Back To Schedule
Monday, June 15 • 8:00am - 10:00am
#100 SL: DIA Global Annual Meeting – Opening DIAmond and Plenary Session

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Forum
Level: Intermediate
CE: ACPE 1.50 Knowledge UAN: 0286-0000-20-525-L04-P; CME 1.50; IACET 1.50; RN 1.50

We are excited to welcome you to the DIA 2020 Virtual Global Annual Meeting
Join us for the Global Annual Meeting Welcome Remarks, Keynote Address, and Opening DIAmond Session!

Keynote Address: Confessions of a "Human Subject" - Can We Put the Humanity in Scientific Study?
When Mary Elizabeth Williams was diagnosed with metastatic cancer and trying to get into an odds-defying clinical trial, a clinician at her hospital casually introduced her to his research fellows as "the tumor." Science is advancing, but what good is it if patients feel alienated? Journalist and author Williams will discuss why the treatment plan process must understand the emotional and logistical needs of the patient, and how humanity is an essential element of successful healthcare outcomes.

DIAmond Session:

In this thought-provoking session, top leaders will discuss how the COVID-19 crisis is shaping the future of drug development. They will look back on the world’s response to the pandemic and what that has revealed about our preparedness to manage a crisis of this proportion. How will learnings be applied in the post-COVID environment? The panel will discuss forward-looking efforts being implemented and how collaboration and innovative thinking will be crucial to our ability to better prepare for “the next time.”

Learning Objectives

Discuss why treatment plans must address the emotional and logistical needs of the patient in advancing science; Identify how forward-looking efforts are shaping the future of drug development as a result of the COVID-19 crisis; Evaluate how collaborative and innovative thinking can better prepare for next pandemic.


Barbara Lopez Kunz, MSc


Honorary Chair
Michelle Rohrer, PhD

Keynote Address
Maryelizabeth Williams

DIAmond Session: Emerging from the COVID-19 Crisis: Innovation Will Not Be Optional
Elizabeth Garner, MD, MPH

Dalvir Gill, PhD

Michelle Rohrer, PhD

Rod MacKenzie, PhD

Christopher P. Austin, MD

Doris Rouse, PhD

avatar for Barbara Lopez Kunz

Barbara Lopez Kunz

Global Chief Executive, DIA, United States
Barbara Lopez Kunz serves as President and Global Chief Executive of DIA, driving thought leadership and innovation in therapeutic development to improve the health of people worldwide. She previously served as President of Health and Life Sciences at Battelle, one of the world’s... Read More →
avatar for Michelle Rohrer

Michelle Rohrer

Senior Vice President, Global Head of Product Development Regulatory and Policy, Roche Genentech
Michelle Rohrer, PhD is Global Head of Product Development Regulatory and Policy, as well as the ad interim Global Head of Medical Affairs for Roche Genentech. Michelle has worked at the company for 27 years, starting as a post-doctoral fellow. She has worked as a clinical scientist... Read More →
avatar for Maryelizabeth Williams

Maryelizabeth Williams

Writer, Speaker, Consultant, maryelizabethwilliams.net
Mary Elizabeth Williams is a journalist and author. In 2011, facing metastatic melanoma, she became one of the first people in the world in an innovative immunotherapy clinical trial -- and twelve weeks later showed a complete response. She chronicled her experience in the nonfiction... Read More →
avatar for Elizabeth Garner

Elizabeth Garner

Chief Medical Officer, ObsEva SA
Elizabeth Garner, MD, MPH completed her medical training at Harvard Medical School and Harvard School of Public Health.
avatar for Christopher Austin

Christopher Austin

Director, National Center for Advancing Translational Sciences, National Institutes of Health (NIH)
Christopher P. Austin has served as director of the NCATS since 2012. Prior to this role, he was NCATS’ scientific director, focusing on translating basic science discoveries into new treatments and technologies to improve the efficiency of therapeutic/diagnostic development. He... Read More →
avatar for Dalvir Gill

Dalvir Gill

Chief Executive Officer, TransCelerate BioPharma Inc., United States
Dalvir Gill has more than 30 years of drug development & leadership experience. Prior to his appointment as CEO of TransCelerate, he was the President of a major international CRO. Dr. Gill earned his BSc from the University of Hertfordshire and his PhD from the Royal Free Hospital... Read More →
avatar for Rod Mackenzie

Rod Mackenzie

Executive Vice President, Chief Development Officer, Pfizer Inc
Chief Development Officer and Executive Vice President for Pfizer. Rod leads the Global Product Development organization and is responsible for the clinical development of Pfizer’s pipeline of innovative medicines, as well as regulatory affairs in support of Pfizer’s R&D portfolio... Read More →
avatar for Doris Rouse

Doris Rouse

Vice President, Global Health Technologies, RTI International
Doris Rouse, PhD, manages the coordination of diverse disciplines to address major global health needs. Dr. Rouse’s research interests include development of new drugs and drug therapies to combat antibiotic resistance and antimicrobial resistant strains of bacteria. She leads a... Read More →

Monday June 15, 2020 8:00am - 10:00am EDT
TBD Virtual Event Horsham, PA 19044
  00: Plenary, Forum |   20: DIAmond, Forum